| Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia SG O'Brien, F Guilhot, RA Larson, I Gathmann, M Baccarani, F Cervantes, ... New England Journal of Medicine 348 (11), 994-1004, 2003 | 4654 | 2003 |
| Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia BJ Druker, F Guilhot, SG O'Brien, I Gathmann, H Kantarjian, N Gattermann, ... New England Journal of Medicine 355 (23), 2408-2417, 2006 | 4413 | 2006 |
| Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia H Kantarjian, C Sawyers, A Hochhaus, F Guilhot, C Schiffer, ... New England Journal of Medicine 346 (9), 645-652, 2002 | 2692 | 2002 |
| European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 M Baccarani, MW Deininger, G Rosti, A Hochhaus, S Soverini, ... Blood, The Journal of the American Society of Hematology 122 (6), 872-884, 2013 | 2577 | 2013 |
| Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype B Falini, C Mecucci, E Tiacci, M Alcalay, R Rosati, L Pasqualucci, ... New England Journal of Medicine 352 (3), 254-266, 2005 | 2304 | 2005 |
| Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia G Saglio, DW Kim, S Issaragrisil, P Le Coutre, G Etienne, C Lobo, ... New England Journal of Medicine 362 (24), 2251-2259, 2010 | 2104 | 2010 |
| Standardization and quality control studies of ‘real-time’quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection … J Gabert, E Beillard, VHJ Van der Velden, W Bi, D Grimwade, ... Leukemia 17 (12), 2318-2357, 2003 | 1914 | 2003 |
| Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet M Baccarani, J Cortes, F Pane, D Niederwieser, G Saglio, J Apperley, ... Journal of clinical oncology 27 (35), 6041, 2009 | 1869 | 2009 |
| Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet M Baccarani, G Saglio, J Goldman, A Hochhaus, B Simonsson, ... Blood 108 (6), 1809-1820, 2006 | 1833 | 2006 |
| Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease JJM Van Dongen, EA Macintyre, JA Gabert, E Delabesse, V Rossi, ... Leukemia 13 (12), 1901-1928, 1999 | 1539 | 1999 |
| Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL … T Hughes, M Deininger, A Hochhaus, S Branford, J Radich, J Kaeda, ... Blood 108 (1), 28-37, 2006 | 1535 | 2006 |
| European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia A Hochhaus, M Baccarani, RT Silver, C Schiffer, JF Apperley, F Cervantes, ... Leukemia 34 (4), 966-984, 2020 | 1270 | 2020 |
| Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’quantitative reverse-transcriptase polymerase chain … E Beillard, N Pallisgaard, VHJ Van der Velden, W Bi, R Dee, ... Leukemia 17 (12), 2474-2486, 2003 | 1100 | 2003 |
| Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial JE Cortes, G Saglio, HM Kantarjian, M Baccarani, J Mayer, C Boqué, ... Journal of Clinical Oncology 34 (20), 2333, 2016 | 976 | 2016 |
| Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial A Hochhaus, G Saglio, TP Hughes, RA Larson, DW Kim, S Issaragrisil, ... Leukemia 30 (5), 1044-1054, 2016 | 883 | 2016 |
| BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European … S Soverini, A Hochhaus, FE Nicolini, F Gruber, T Lange, G Saglio, F Pane, ... Blood, The Journal of the American Society of Hematology 118 (5), 1208-1215, 2011 | 730 | 2011 |
| PML targeting eradicates quiescent leukaemia-initiating cells K Ito, R Bernardi, A Morotti, S Matsuoka, G Saglio, Y Ikeda, J Rosenblatt, ... Nature 453 (7198), 1072-1078, 2008 | 693 | 2008 |
| The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts Experts in Chronic Myeloid Leukemia Blood, The Journal of the American Society of Hematology 121 (22), 4439-4442, 2013 | 658 | 2013 |
| Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy F Mandelli, D Diverio, G Avvisati, A Luciano, T Barbui, C Bernasconi, ... Blood, The Journal of the American Society of Hematology 90 (3), 1014-1021, 1997 | 646 | 1997 |
| Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia S Soverini, S Colarossi, A Gnani, G Rosti, F Castagnetti, A Poerio, ... Clinical Cancer Research 12 (24), 7374-7379, 2006 | 639 | 2006 |
Massimo MassaiaAssociate Professor Hematology - Director Hematology Division, Cuneo, Italy在 unito.it 的电子邮件经过验证
Massimo MassaiaAssociate Professor Hematology - Director Hematology Division, Cuneo, Italy在 unito.it 的电子邮件经过验证